Study shows new indication for AngioMark
In a preliminary clinical study codesigned by pharmaceutical firm Pfizer and researchers at the University of Washington Medical School, intravascular MRI contrast agent AngioMark has been shown effective in identifying and measuring the physiological
In a preliminary clinical study codesigned by pharmaceutical firm Pfizer and researchers at the University of Washington Medical School, intravascular MRI contrast agent AngioMark has been shown effective in identifying and measuring the physiological changes that occur during female sexual arousal. The study, presented at the RSNA conference in December, used Epix Medicals agentwhich it is developing in collaboration with Mallinckrodt of St. Louisto show how blood volume to the pelvic region increases during sexual arousal in women.
Eight healthy pre- and postmenopausal women were included in the study, which researchers hope will boost future efforts to determine how treatments for impaired sexual response and how various diseases affect sexual response in women, according to Dr. Wayne Carter of Pfizer Central Research.
AngioMark is in phase III trials to demonstrate its efficacy in detecting aortoiliac occlusive disease in patients with peripheral vascular disease or abdominal aortic aneurysm. In 1998, Cambridge, MA-based Epix and Pfizer forged an alliance to research the efficacy of AngioMark and MRI technology to diagnose and monitor female sexual arousal dysfunction. Pfizer developed and markets Viagra for erectile dysfunction in men.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
